SCM
PRAX icon

Silverarc Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Silverarc Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22M Sell
65,679
-5,873
-8% -$1.86M 2.29% 16
2026
Q1 		$23.1M Sell
71,552
-10,913
-13% -$3.38M 2.35% 15
2025
Q4 		$24.3M Buy
82,465
+31,255
+61% +$5.82M 3.38% 9
2025
Q3 		$2.71M Buy
51,210
+41,210
+412% +$2M 0.37% 58
2025
Q2 		$421K Sell
10,000
-156,074
-94% -$5.94M 0.08% 58
2025
Q1 		$6.29M Buy
166,074
+93,558
+129% +$5.84M 1.29% 26
2024
Q4 		$5.58M Buy
72,516
+5,471
+8% +$396K 1.22% 29
2024
Q3 		$3.86M Sell
67,045
-251
-0.4% -$13.6K 0.87% 37
2024
Q2 		$2.78M Sell
67,296
-123,260
-65% -$5.83M 0.66% 37
2024
Q1 		$11.6M Sell
190,556
-93,285
-33% -$4.18M 3.23% 10
2023
Q4 		$6.32M Buy
283,841
+9,313
+3% +$168K 1.88% 18
2023
Q3 		$7.04M Buy
274,528
+42,784
+18% +$809K 2.14% 15
2023
Q2 		$4M Buy
+231,744
New +$3.55M 1.24% 28
2023
Q1 		– Sell
-6,561
Closed -$234K – 97
2022
Q4 		$234K Sell
6,561
-106
-2% -$3.31K 0.07% 83
2022
Q3 		$227K Buy
+6,667
New +$332K 0.08% 73

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Silverarc Capital Management's PRAX Position: Q2 2026 in Review

Silverarc Capital Management reduced its Praxis Precision Medicines (PRAX) stake by 8.2% in Q2 2026, selling an estimated $1.86M and leaving 65,679 shares worth $22M. The position accounts for 2.29% of the portfolio, ranked #16.

Silverarc Capital Management first reported a position in PRAX in Q3 2022 and has held it in 15 quarters since. The position peaked at $24.3M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Silverarc Capital Management held 65,679 shares of Praxis Precision Medicines worth $22M as of Q2 2026.
  • Silverarc Capital Management sold 5,873 Praxis Precision Medicines shares in Q2 2026, an estimated $1.86M.
  • Praxis Precision Medicines made up 2.29% of Silverarc Capital Management's portfolio in Q2 2026, its #16 holding.
  • Silverarc Capital Management first reported a position in Praxis Precision Medicines in Q3 2022 and has held it in 15 quarters since.
  • Silverarc Capital Management's Praxis Precision Medicines position peaked at $24.3M in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.